Table 1.
Clinicopathological Characteristics of Patients with LAPC Stratified by Treatment
| Variable | Treatment | N | P | Variable | Treatment | N | P | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IRE | IRE+Toripalimab | 85 | IRE | IRE+Toripalimab | 85 | ||||||
| Age (years) | ≤60 | 41 (58.6%) | 10 (66.7%) | 51 | 0.772 | CRP (ng/L) | ≤3 | 43 (61.4%) | 11 (73.3%) | 54 | 0.556 |
| >60 | 29 (41.4%) | 5 (33.3%) | 34 | >3 | 27 (38.6%) | 4 (26.7%) | 31 | ||||
| Gender | Male | 30 (42.9%) | 8 (53.3%) | 38 | 0.570 | CEA (ng/mL) | ≤5 | 47 (67.1%) | 7 (46.7%) | 54 | 0.151 |
| Female | 40 (57.1%) | 7 (46.7%) | 47 | >5 | 23 (32.8%) | 8 (53.3%) | 31 | ||||
| WBC (*109) | ≤10 | 66 (94.3%) | 15 (100%) | 81 | 0.453 | CA19-9 (U/mL) | ≤35 | 21 (30.0%) | 4 (26.7%) | 25 | 0.533 |
| >10 | 4 (5.7%) | 0 (0) | 4 | >35 | 49 (70.0%) | 11 (73.3%) | 60 | ||||
| HGB (g/L) | ≤175 | 17 (24.3%) | 1 (6.7%) | 18 | 0.175 | CA125 | ≤35 | 43 (61.4%) | 11 (73.3%) | 54 | 0.482 |
| >175 | 53 (75.7%) | 14 (93.3%) | 67 | >35 | 27 (38.6%) | 4 (26.7%) | 31 | ||||
| PLT (*109) | ≤350 | 61 (87.1%) | 14 (93.1%) | 75 | 0.683 | HBsAg | Absence | 64 (91.4%) | 15 (100%) | 79 | 0.585 |
| >350 | 9 (12.9%) | 1 (6.7%) | 10 | Presence | 6 (8.6%) | 0 (0) | 6 | ||||
| ALT (U/L) | ≤50 | 55 (78.6%) | 15 (100%) | 70 | 0.062 | Tumor grade | Well | 41 (58.6%) | 7 (46.7%) | 48 | 0.409 |
| >50 | 15 (21.4%) | 0 (0) | 15 | Moderate/Poor | 29 (41.4%) | 8 (53.3%) | 37 | ||||
| AST (U/L) | ≤40 | 55 (78.6%) | 15 (100%) | 70 | 0.062 | Tumor size (cm) | ≤2 | 4 (5.7%) | 3 (20.0%) | 7 | 0.184 |
| >40 | 15 (21.4%) | 0 (0) | 15 | 2~4 | 36 (51.4%) | 7 (46.7%) | 43 | ||||
| ALP (U/L) | ≤125 | 45 (64.3%) | 13 (86.7%) | 58 | 0.129 | >4 | 30 (42.9%) | 5 (33.3%) | 35 | ||
| >125 | 25 (35.7%) | 2 (13.3%) | 27 | Tumor site | Head | 36 (51.4%) | 6 (40.0%) | 42 | 0.571 | ||
| GGT (U/L) | ≤60 | 40 (57.1%) | 11 (73.3%) | 51 | 0.384 | Body/tail | 34 (48.6%) | 9 (60.0%) | 43 | ||
| >60 | 30 (42.9%) | 4 (26.7%) | 34 | Chemotherapy before IRE | Absence | 26 (37.1%) | 5 (33.3%) | 31 | 0.514 | ||
| ALB (g/L) | >40 | 11 (15.7%) | 1 (6.7%) | 12 | 0.683 | Presence | 44 (62.9%) | 10 (66.7%) | 54 | ||
| ≤40 | 59 (84.3%) | 14 (93.3%) | 73 | Chemotherapy type before IRE | S-1 | 26 (37.2%) | 5 (33.3%) | 31 | 0.710 | ||
| TBIL (umol/L) | ≤20.5 | 56 (80.0%) | 15 (100%) | 71 | 0.066 | AG | 19 (27.1%) | 3 (20.0%) | 22 | ||
| >20.5 | 14 (20.0%) | 0 (0) | 14 | FOLFIRINOX | 25 (35.7%) | 7 (46.7%) | 32 | ||||
| IBIL (umol/L) | ≤15 | 60 (85.7%) | 15 (100%) | 75 | 0.197 | ||||||
| >15 | 10 (14.3%) | 0 (0) | 10 | ||||||||
Abbreviations: WBC, white blood cell; PLT, platelet; ALT, alanine transaminase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, glutamyl transpeptidase; ALB, albumin; TBIL, total bilirubin; IBIL, indirect bilirubin; CRP, C-reactive protein; HBsAg, hepatitis B surface antigen; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; AG, Abraxane-GEM; FOLFIRINOX, leucovorin, fluorouracil, irinotecan, and oxaliplatin.